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Abstract
Background: Inappropriate use of antidepressants (AD), defined as either continuation in the absence of a proper
indication or continuation despite the lack of therapeutic efficacy, applies to approximately half of all long term AD
users.
Methods/design: We have designed a cluster randomized controlled clinical trial to assess the (cost-) effectiveness
of an antidepressant cessation advice in the absence of a proper indication for maintenance treatment with
antidepressants in primary care.
We will select all patients using antidepressants for over 9 months from 45 general practices. Patients will be
diagnosed using the Composite International Diagnostic Interview (CIDI) version 3.0, extended with questions about
the psychiatric history and previous treatment strategies. General practices will be randomized to either the
intervention or the control group. In case of overtreatment, defined as the absence of a proper indication
according to current guidelines, a cessation advice is given to the general practitioner. In the control groups no
specific information is given. The primary outcome measure will be the proportion of patients that successfully
discontinue their antidepressants at one-year follow-up. Secondary outcomes are dimensional measures of
psychopathology and costs.
Discussion: This study protocol provides a detailed overview of the design of the trial. Study results will be of
importance for refining current guidelines. If the intervention is effective it can be used in managed care programs.
Trial registration: NTR2032
Keywords: Depression, Anxiety, Composite International Diagnostic Interview (CIDI), Randomized controlled trial,
General practice, Depressive disorder, Anxiety disorders
Background
Depressive- and anxiety disorders are among the most
prevalent disorders, with lifetime prevalence rates of
19% for both [1]. Most patients with depressive- and
anxiety disorders are treated in general practice. In the
last decade of the 20th century, prescription rates for
antidepressants have increased 4 to 10 times in general
practice [2,3]. Currently, 2.1–2.5% of patients treated in
primary care receive antidepressants for 9 months or
longer, i.e. 50–60 patients per average Dutch general
practice with 2350 patients [4]. The appropriateness of
long-term antidepressant usage is a matter of debate [5].
From a patient perspective, inappropriate use of antide-
pressants has serious consequences for safety, wellbeing
and daily functioning [5]. Also there are negative side
effects such as sexual disorder, emotional flattening,
interaction with other drugs and sedation [6]. From an
economic perspective, inappropriate use of antidepres-
sants is expensive considering the high costs of modern
antidepressant drugs in the case of overtreatment and
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the high costs for productivity loss due to depressive
and anxiety disorders in the case of undertreatment. Al-
though the Dutch NEMESIS data show that half of the
identified antidepressant drug users still suffered from a
depressive or anxiety disorder [5] and are thus in need
of subsequent treatment steps we considered this type of
inappropriate treatment beyond the scope of the study
reported here.
Current guidelines advise to continue treatment with
antidepressants for 6 months after remission for a first or
second depressive episode or a successfully treated anxiety
disorder, which means a total treatment duration of ap-
proximately 9 months [7,8]. Overtreatment is therefore
defined as the continued prescription of antidepressants
without an appropriate indication at start or continued pre-
scription during more than 6 months after remission of the
index disorder. There is evidence of overtreatment in pri-
mary care. Antidepressants are often initiated during the
first consultation with the general practitioner (GP) about
emotional symptoms [9]. Moreover, up to 80% of the users
receive antidepressants for mild to moderate depressions
[4,10-12], while 60% of these depressions remit spontan-
eously within 6 months [5]. The Netherlands Mental
Health Survey and Incidence Study, has shown that about
half of the antidepressant drug users in the community did
not meet the criteria for a depressive or anxiety disorder in
the past six months. Similar results were found in chart-
review studies, showing that GPs had not registered a psy-
chiatric diagnosis in nearly 40% of patients receiving pre-
scriptions for antidepressant drugs. [3,4,13] Furthermore,
10–15% of long-term antidepressant drug users continue
usage after remission without trying to discontinue it.
Aims of the study
The aim of this study is to reduce ‘overtreatment’, i.e.
long-term use of antidepressants (>9 months) in the ab-
sence of an indication for maintenance treatment with
antidepressants according to current guidelines. We will
evaluate the (cost-)effectiveness of a cessation advice to
the general practitioner based on a detailed patient as-
sessment in general practice.
Study hypotheses
The main hypothesis is that the intervention will lead to
a higher reduction in antidepressant usage as well as
lower (in)direct costs compared to the control condition.
A second hypothesis is that these gains will be achieved
without deterioration of psychological functioning.
Methods/design
Design of the trial
This study consists of a randomised controlled parallel-
group trial, which will be conducted in general practice (see
Figure 1 for an overview). Patients using antidepressants
for at least nine months or longer are eligible for par-
ticipation. Potentially eligible patients will be identified
within the computerised prescription databases of the
participating general practices. The GP will check the
exclusion criteria (see below) for the patients on these
generated lists. After a structured psychiatric interview
using the Composite International Diagnostic Inter-
view (CIDI) 3.0 [14] with added detailed questions
about psychiatric history and treatment, patients meet-
ing the inclusion criteria will included in the trial. In
case of undertreatment, i.e. the presence of a psychi-
atric diagnosis despite long-term antidepressant usage,
patients will be offered to participate in a second trial
that will be conducted in tandem (see trial registration
database: NTR2032). As we failed to recruit sufficient
patients for this second trial, no further details will be
given here.
The primary outcome measure is successful discon-
tinuation of antidepressant drug use, defined as no use
of antidepressants during the 6–12 month follow-up in
the absence of a psychiatric disorder. At the 12-month
follow-up, the CIDI 3.0 will be re-administered by an
interviewer blind for baseline results. Secondary out-
come measures include a detailed set of dimensional
measures of psychopathology, quality of life and costs
(see below) administered at baseline and at 3, 6, 9, and
12 months follow-up (see below).
Setting
The study will be conducted in general practice. Be-
tween February 2010 and January 2012, a total of 56
general practices were contacted for participation of
which 45 practices (response rate 80.3%) have actually
participated in the study: 31 practices from the Primary
Care Network of the Radboud University Nijmegen
Medical Centre and 14 practices not connected with this
network.
Patients
Eligibility assessment
Patient recruitment took place between May 2010 and
May 2012. General practitioners systematically identified
all users of antidepressants using the prescription
records of their electronic medical records (supported
by our research team). However, GPs were able to ex-
clude long-term users a priori based on the exclusion
criteria (known to them) or specific reasons that had to
be specified per patient. All remaining patients using
antidepressants for over nine months were considered
eligible and received written information about the
study. Those who consented to participate were con-
tacted by the researcher for further information and
screened once more on the in- en exclusion criteria.
Patients who still met the criteria received a formal
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appointment for structured psychiatric interview by tele-
phone using the Composite International Diagnostic
Interview, version 3.0 (CIDI 3.0).
Inclusion criteria
1. Having received prescriptions for antidepressants for
at least nine months in an amount sufficient for at
least 270 days of use according to the prescribed
dosage extracted from the electronic prescription
records. Except for MAO-inhibitors, all types of
antidepressants are included in this study. We do not
include patients who receive MAO-inhibitors
because these drugs can only be prescribed by
psychiatrists in the Netherlands.
2. Having given written informed consent before the
date of the psychiatric interview.
Exclusion criteria
1. Appropriate use of long-term antidepressants
according to the Dutch guidelines for depressive and
anxiety disorders, i.e. a) a history of recurrent
depression with 3 or more episodes and/or a
recurrent psychiatric disorder with at least two
relapses after antidepressant-discontinuation.
2. Presence of a current psychiatric diagnosis for which
antidepressants may be effective, i.e. depressive
disorder, dysthymia, generalised anxiety disorder,
panic disorder, or social phobia).
3. Current treatment in a psychiatric setting
4. History of psychosis, bipolar disorder, or obsessive
compulsive disorder
5. Current diagnosis of substance use disorder;
6. Non-psychiatric indication for long-term
antidepressant usage, e.g. neuropathic pain
7. Inability to perform the necessary assessment due to
a hearing impairment (telephonic interview) and/or
not understanding Dutch language (telephonic
interview and survey).
A total number of 146 patients have been included.
The one-year follow up interviews have started in May
2011 and are still going on, expectedly till May 2013.
Randomization
To prevent contamination between intervention and
control group a cluster randomisation is performed with
Long-term usage of antidepressants (>9 months) 
General practices 
Domain population (Inclusion criteria) 
General practices 
Exclusion criteria after a diagnostic work-up: 
1. Appropriate prescription 
2. Psychiatric diagnosis requiring further treatment * 
Dropout (exclusion criteria checked by GP) 
Discontinuation 
 antidepressant 
Usual care  
(no intervention) 
Psychiatric diagnostic interview  
(CIDI with additional questions) 
No informed consent 
Randomisation 
of general 
practices 
NO psychiatric diagnosis 
NO indication for continuation of antidepressant 
Figure 1 Study flowchart cluster randomisation. * Informed consent will be asked for a randomised controlled trial conducted in tandem to
improve ‘undertreatment’ in long-term antidepressant users. Abbreviations: GP, general practitioner; CIDI, Composite International Diagnostic
Interview.
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the general practice as the unit of clustering. Random
assignment was ensured by picking a sealed envelope
with intervention or control group after patient recruit-
ment had been concluded in that particular practice.
The cessation advices will only be sent to the GPs from
practices allocated to the intervention group. GPs from
practices in the control group are asked to continue
their usual care, as if they were not participating in this
trial. Interviewers who conducted the baseline and
follow-up interviews as well as the psychiatrist and gen-
eral practitioner who judged the indication of mainten-
ance treatment will remain blinded throughout the trial.
Intervention
The intervention implies the discontinuation of anti-
depressant use, following the recommendations in the
Dutch multidisciplinary guidelines for depressive and
anxiety disorders [15]. These are similar to those in the
British NICE guidelines, recommending strict indica-
tions for the initiation, continuation and discontinuation
of antidepressants [7]. Although in a recent meta-
analysis patients with a single depressive episode showed
no difference in relapse rates between abrupt and grad-
ual antidepressant discontinuation [16], we advised a
gradual tapering program for the following reasons: 1)
abrupt discontinuation may trigger a relapse in patients
who suffered from an anxiety disorder or a recurrent
depressive disorder at the time of initiating the
antidepressant [16], and 2) discontinuation symptoms
occur more frequently in patients who abruptly discon-
tinue their antidepressants than in patients whose
treatment is gradually tapered [17,18]. The general prac-
titioner receives a letter stating that the patient does not
meet the criteria for a depressive or anxiety disorder in
the past six months. In addition, he or she receives an
information sheet with current guidelines on antidepres-
sant tapering and information about the discontinuation
syndrome [19], including a detailed scheme for tapering
for each patient (see Table 1). Duration of tapering was
primarily based on the dosage and the half-life of the dif-
ferent antidepressants. No treatment restrictions are
imposed on GP or patient in case of relapse or onset of
a new psychiatric disorder after discontinuation.
A psychiatrist (RCOV) and a general practitioner (PL)
will compare the diagnostics and treatment history of
patients who underwent a full baseline examination with
current guidelines independently. The decision for a ces-
sation advise will be based on the Dutch Multidisciplin-
ary Guidelines for the treatment of depressive disorder
and of anxiety disorders [15]. These Multidisciplinary
Guidelines provide detailed information and a treatment
algorithm for all depressive and anxiety disorders. In a
case of incongruent advices the psychiatrist and the gen-
eral practitioner will discuss the case until they reach
consensus. Incongruence between the GP and psych-
iatrist will be reported as percentage disagreement.
Table 1 Applied schemes for tapering long-term antidepressant usage in primary care
Antidepressant AD tapering scheme (steps per 2 weeks, dose in mg/day)
Start dose Step 1 Step 2 Step 3 Step 4
TCA
• Amitriptyline > 150 150 100 50 25
• Imipramine > 150 150 100 50 25
• Nortriptyline > 150 150 100 50 25
• Clomipramine > 150 150 100 50 25
SSRI
• Fluoxetine > 60 40 30 20 10
• Paroxetine > 40 40 30 20 10
• Sertraline > 150 150 100 50 25
• Citalopram > 40 40 30 20 10
• Escitalopram > 20 20 15 10 5
• Fluvoxamine > 150 150 100 50 25
Other antidepressants
• Mirtazapine > 45 45 30 15 -
• Duloxetine > 120 120 90 60 30
• Venlafaxine > 150 150 112.5 75 37.5
• Trazodon > 150 150 100 50 -
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When they are unable to reach consensus, advice will be
asked from another couple consisting of a GP (CvW)
and a psychiatrist (AS).
To check the reliability of the proposals by the GP and
psychiatrist, we provided another GP (CvW) and psych-
iatrist (AS) with 10 randomly selected case vignettes
from included patients. Comparing these judgments,
there was a 100% agreement.
Control condition
The control condition will consist of usual care and do
not impose restrictions on GPs to deliver care or to refer
to specialised mental health care, including the continu-
ation or discontinuation of psychotropic drugs. Since
baseline psychiatric diagnostics will not be disclosed for
patients who have given informed consent in a control
practice (also those with appropriate use or undertreat-
ment), we expect continuation of antidepressant drug
treatment in most cases [13].
Assessments
Eligible patients who consent for participation will re-
ceive a psychiatric interview by telephone, using the
depression and anxiety part of the Composite Inter-
national Diagnostic Interview (CIDI) [20,21] as well as
the sections on social phobia, bipolar disorder, general-
ized anxiety disorder, neurasthenia, specific phobia and
obsessive compulsive disorder. The CIDI is a structured
and fully standardized psychiatric interview for diag-
nosing mental disorders according to ICD and DSM-
IV criteria.
The CIDI interview can be done by trained laymen,
and thus imposes no restrictions on the interviewers.
Furthermore, telephonic administration of the CIDI has
been demonstrated feasible and reliably [20,21]. To en-
able the preparation of treatment proposal, the CIDI
interview was extended with detailed questions about
previously used psychotropic drugs (duration and
dosages) and psychosocial therapies. In case of psycho-
therapy, predefined questions were asked to discern be-
tween cognitive-behavioral interventions, interpersonal
therapy and/or structured/supportive therapy. In addition,
demographic variables, the use of psychoactive sub-
stances (nicotine, alcohol, and drugs), screening of post-
traumatic stress disorder, and the presence of chronic
somatic disorders will be recorded at the baseline inter-
view. The CIDI 3.0 interview will be repeated after one-
year follow-up.
Subsequently, all patients will fill out a set of self-
report questionnaires at baseline and at 3, 6, 9 and
12 months follow-up (see secondary outcome mea-
sures below).
Personality characteristics and the quality of the
patient-physician relationship have been suggested to
affect treatment outcome of common mental disorders
in primary care. Therefore, these characteristics will be
examined additionally at baseline by administration of
the NEO-Five Factor Inventory (NEO-FFI) [22] and the
Patient Doctor Relation questionnaire (PDRQ) [23].
Primary outcome measures
The primary outcome is the proportion of participants
who successfully discontinue their long-term antidepres-
sive drug use. This is defined as having no antidepres-
sant drug use within the last 6 months of the follow-up
and the absence of a depressive or anxiety disorder dur-
ing one-year follow-up as assessed with the CIDI 3.0.
Use of antidepressants will be evaluated with questions
during this second CIDI interview as well as with self-
report questionnaires. In case of inconsistencies between
both measures, the patient will be re-contacted and if
necessary the GP will be contacted to check the GP pre-
scription database. This latter solution is considered reli-
able as in the Netherlands all patients are linked to only
one GP who collects all medical information for that
patient.
Secondary outcome measures
Secondary outcome measures are the severity of psycho-
logical symptoms, quality of life, costs and also the
prevalence of discontinuation symptoms. We have only
included self-report questionnaires that are validated in
Dutch and have shown good to excellent psychometric
properties.
The overall severity of psychological distress and glo-
bal psychopathology will be based on the Brief Symptom
Inventory (BSI-53) sum score. The BSI-53 is a shortened
version of the Symptom Checklist (SCL) 90-item version
[24] with similar psychometric characteristics and sub-
scales, but less patient burden [25].
For more detailed evaluation, we also included dis-
order specific instruments:
– The Centre for Epidemiological Studies Depression
Scale (CES-D) for measuring the severity depressive
symptoms [26];
– The Penn State Worry Questionnaire (PSWQ) for
assessing the frequency and severity of symptoms of
worrying [27];
– The Panic and Agoraphobic Scale (PAS) for
measuring the severity of illness in patients with
panic disorder [28];
– The Fear of Negative Evaluation Scale (FNES) for
assessing expectations and distress associated with
negative evaluations by others [29];
The EuroQol-5D (EQ-5D) offers the possibility to
evaluate effects of quality of life, although this
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questionnaire is primarily included to enable the eco-
nomic analyses by providing a utility score [30-33]. The
EQ-5D has previously been validated and has been ap-
plied successfully in studies of depressive and anxiety
disorders.
Costs will be measured by the Trimbos/iMTA ques-
tionnaire for Costs associated with Psychiatric Illness
(TiC-P) [34].
Finally, the prevalence and severity of an antidepressant
discontinuation syndrome will be measured in those who
withdraw from medication using the Discontinuation-
Emergent Signs and Symptoms (DESS) Scale [35]. This
latter scale, however, has not been validated in Dutch.
Power
A senior academic statistician using SAS POWER pro-
cedure performed a prospective sample size calculation.
It aimed to determine a target sample size that would
provide at least 85% power for two-tailed testing (at a
type-1 error rate of 5%). Because our trial is cluster ran-
domized, calculations to determine the minimum number
of general practices is stricter than in a non-clustered trial.
To account for this, we used an intra-class correlation
(ICC) of 0.05.
Assumptions with respect to recruitment and outcome
are difficult to estimate. We expect a 20% discontinu-
ation rate for patients in the control group, and a 50%
discontinuation rate in the intervention group. The 20%
discontinuation rate is conservatively estimated (prob-
ably lower than 20%) based on the fact that in the
Netherlands, the rate of spontaneous non-adherence to
antidepressant drug therapy has been estimated at 25%
within the first 6 months [36]. This rate is expected to
decline gradually as the treatment time elapses (as those
patients with initial side-effects have already dropped
out). The 50% discontinuation rate is based on the
results of a primary care benzodiazepine discontinuation
study of our group [37,38]. This is also considered
conservative, as in contrast to benzodiazepines, psy-
chological dependency does not play a major role in
long-term use of antidepressants.
The recruitment rate was originally based on a
small qualitative pilot study assuming that one aver-
age general practice would enable to include 6
patients in the trial. Assuming a dropout rate of
25%, a total of 20 practices (160 patients) had to be
recruited. As the number of patients recruited per
practice was lower than expected, we recruited more
practices for participation in the study. A total of 45
practices finally participated in the study, which
resulted in the recruitment of 146 patients. Based on
our a priori assumptions of the success rates and
drop out rates, we will have over 85% power.
Data analysis and treatment effect
Descriptive statistics
The trial has a binary primary outcome, i.e. successful
discontinuation yes or no, and dimensional secondary
outcome parameters. In order to check for baseline dif-
ferences between the two groups, a series of univariate
analyses (t-tests, chi-square tests, Mann–Whitney tests)
on psychiatric status and demographic variables will
be performed.
Multilevel analysis
Multilevel analyses will be used to account for the hier-
archical structure of the data (i.e. patients nested within
practices). Covariates (see above) will be included if they
show a relationship with the outcome. The secondary
outcome measures (continuous variables) will be ana-
lysed by using the mixed procedure in SAS. Firstly, a
general comparison will be made based on the BSI-53
(general distress), which is applicable to all patients. Sec-
ondly, disease-specific instruments will be pooled after
having determined the most relevant disease-specific
questionnaire for each patient based on one’s primary
diagnosis assessed with the CIDI at study entry (i.e. de-
pressive disorder, panic disorder, generalized anxiety dis-
order or social phobia). The scores on the different
questionnaires will be transformed into standardized t-
scores, in order to pool these data in multilevel analysis
for continuous variables. In case the CIDI at baseline
will not identify any psychiatric disorder for which the
antidepressant drug treatment has been initiated, the
BSI-53 score will be taken.
All analyses will be performed on an intention-to-treat
basis. Patients who dropped out will be classified as fail-
ure (for the primary outcome variables). For the second-
ary outcome measures, missing values will be imputed
by multiple imputation techniques.
Interim analysis
The investigators do not expect any serious adverse
events that will require an interim analysis to make a de-
liberate consideration of terminating the study earlier
than planned (approved by the institutional ethics com-
mittee). Due to the statistical characteristics of an in-
terim analysis, the achieved power of this study would
be unnecessarily reduced.
Ethical aspects
The trial is registered before start of the study, and will
be reported according to CONSORT guidelines. Our
study is approved by the institutional ethics committee
Nijmegen under registration number NL29718.091.09
and registered in the Netherlands Trial Register
NTR2032.
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Informed consent is obtained from the subjects before
entering the study. Before patients give their consent, a
detailed information package is sent to them, which pro-
vides the aims and characteristics of the study. All sub-
jects are informed that participation in the study is
voluntary and that they are allowed to withdraw from
the study at any time.
Discussion
We have described the study protocol of a cluster-
randomised controlled clinical trial to evaluate the im-
pact of cessation advice to the GP in order to reduce
overtreatment with antidepressants in general practice.
The primary outcome measure is the proportion of
patients that successfully discontinued their antidepres-
sants. Secondary outcomes include dimensional mea-
sures of psychopathology and (in)direct costs.
Cluster randomization
We applied cluster randomization instead of individ-
ual or normal randomization for two reasons [39].
Firstly, randomization at the patient level would in-
evitably have led to contamination, as receiving ces-
sation proposals for some, but not all patients
included from an individual GP, would inevitably
trigger him or her to rethink their strategy of con-
trol patients. During the trial, treatment given to
control patients will probably be contaminated. Sec-
ondly, in our study the patients are nested in general
practices and cannot be considered as statistically in-
dependent. Thus, when not taking into account the
general practice as unit of cluster, this will inflate
type I errors [40].
Generalizability
The study is based on a pilot study, performed before
the PANDA study started. In this pilot study there was a
calculation made how many patients were using antide-
pressants for more than 9 months. We identified signifi-
cantly fewer patients per general practice/general
practitioner who participated in the study. This might
limit the generalizability of our findings. Because of this
finding we performed some recalculations of the power
analysis (as described above). This is not necessarily
problematic, since including fewer patients per practice
will improve the power.
Furthermore, being a primary care study, we cannot
generalise our results to those patients treated in psychi-
atric care. Overtreatment is probably also an issue in
specialised mental health care, although to our know-
ledge exact figures are lacking. We excluded patients
under current treatment in a psychiatric setting to pre-
vent interfering with current specialised treatment.
Nonetheless, most patients suffering from anxiety and/
or depressive disorders are treated in primary care [41].
Two trials in tandem
Classifying long-term users of antidepressants as being
undertreated or overtreated requires a full psychiatric
diagnostic work-up. The necessity and investment of this
psychiatric work-up has led to the decision to conduct
two trials in tandem using one recruitment strategy. Al-
though available data suggested comparable proportions
of patients being over- or undertreated, reality was hard-
hearted. Recruitment rates in both trials were a little dis-
appointing, but for the trial described in this paper we
could include sufficient patients to achieve over 85%
power based on a priori effect-sizes by recruiting more
general practitioners to participate in our project. None-
theless, we failed in recruiting sufficient patients for sec-
ond trial aimed to improve undertreatment, i.e. the
presence of psychiatric disorder despite the use of an
antidepressant (which argues for further treatment steps
in primary care). If not conducted in tandem, recruit-
ment strategies for this second trial that was conducted
parallel to the trial presented could have been elabo-
rated, as done in many other randomised controlled
trials facing recruitment problems. We thus have to con-
clude that our planned efficiency appeared to be inefficient.
Treatment proposals
A psychiatrist and general practitioner made the cessa-
tion proposals independent of each other. The main de-
cision for the present study was to determine whether
patients received the antidepressants appropriately and if
not, whether cessation should be recommended accord-
ing to actual guidelines (in case of overtreatment) or fur-
ther treatment steps should be taken to augment or
change the treatment. Interestingly, the reliability of the
treatment proposals was excellent, as shown by a 100%
agreement between the results of the second psychiatric-
GP couple on 10 randomly chosen patients.
Clinical relevance of this trial (for update of guidelines)
This study aimed to answer questions on the (cost) ef-
fectiveness to taper antidepressant use in patients who
have no recent diagnosis of depression and/or anxiety.
These results will inevitably impact on the current
guidelines. In case of non-discontinuation, more em-
phasis should be paid on strategies to discontinue anti-
depressants in primary care. In case of high relapse rates
after discontinuation, guidelines should be adapted
regarding the duration of maintenance treatment.
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